To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 121 participants.
Also called NCT05908084
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 121 participants
- Sponsor
- Registry
-
NCT05908084
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05908084. Randomized; single masking; primary purpose treatment. Start 2023-09-07 (actual); primary completion 2027-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
- Condition
- End Stage Renal Disease (ESRD)
- Intervention (Biological)
- Acellular Tissue Engineered Vessel (ATEV)
- Intervention (Other)
- AVF
- Lead sponsor
- Humacyte, Inc.
- Collaborator
- IQVIA Biotech
Record details
- Record id
cardio:ct-nct05908084- Content hash
b02f191bea93f7ad3c16133f71dd4bbb63c2e5bf119a8e5d442da29eacc19adc